Comprehensive management of a child with X-linked lymphoproliferative disease undergoing stem cell transplantation: a case report

Anjali Rathee; Rinkal Jangid; Priyanshi Dixit

doi:10.18203/2349-3291.ijcp20242347

Authors

Anjali Rathee Department of Hematology, AIIMS, New Delhi, Delhi, India
Rinkal Jangid Department of Hematology, AIIMS, New Delhi, Delhi, India
Priyanshi Dixit College of Nursing, VMMC and Safdarjung Hospital, New Delhi, Delhi, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20242347

Keywords:

Children, X-linked lymphoproliferative disease, Haploidentical stem cell transplant, Allogenic stem cell transplant

Abstract

An uncommon immunodeficiency disease known as X-linked lymphoproliferative disease (XLP) has been associated with severe immunological dysfunction and a high susceptibility to Epstein-Barr virus (EBV) infections. This case report describes a four-year-old boy who had X-linked lymphoproliferative illness and died from multiple system organ failure (MSOF) after receiving treatment with a haploidentical hematopoietic stem cell transplant (halo-HSCT). While providing care in such circumstances, rational-based care, prompt identification, primary nursing care, health education, and emotional assistance for parents of individuals with X-linked lymphoproliferative diseases are vital.

Metrics

Metrics Loading ...

References

Panchal N, Booth C, Cannons JL, Schwartzberg PL. X-Linked Lymphoproliferative Disease Type 1: A Clinical and Molecular Perspective. Front Immunol. 2018;9:666.

Sumegi J, Huang D, Lanyi A, Davis JD, Seemayer TA, Maeda A, et al. Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood. 2000;96(9):3118-25.

Purtilo DT, Grierson HL, Davis JR, Okano M. The X-linked lymphoproliferative disease: from autopsy toward cloning the gene 1975-1990. Pediatr Pathol. 1991;11(5):685-710.

Morra M, Simarro-Grande M, Martin M, Chen AS, Lanyi A, Silander O, et al. Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients. J Biol Chem. 2001;276(39):36809-16.

Williams LL, Rooney CM, Conley ME, Brenner MK, Krance RA, Heslop HE. Correction of Duncan's syndrome by allogeneic bone marrow transplantation. Lancet. 1993;342(8871):587-8.

Vowels MR, Tang RL, Berdoukas V, Ford D, Thierry D, Purtilo D, et al. Brief report: correction of X-linked lymphoproliferative disease by transplantation of cord-blood stem cells. N Engl J Med. 1993;329(22):1623-5.

Pracher E, Panzer-Grümayer ER, Zoubek A, Peters C, Gadner H. Successful bone marrow transplantation in a boy with X-linked lymphoproliferative syndrome and acute severe infectious mononucleosis. Bone Marrow Transplant. 1994;13(5):655-8.

Gross TG, Filipovich AH, Conley ME, Pracher E, Schmiegelow K, Verdirame JD, et al. Cure of X-linked lymphoproliferative disease (XLP) with allogeneic hematopoietic stem cell transplantation (HSCT): report from the XLP registry. Bone Marrow Transplant. 1996;17(5):741-4.

Ziegner UH, Ochs HD, Schanen C, Feig SA, Seyama K, Futatani T, et al. Unrelated umbilical cord stem cell transplantation for X-linked immunodeficiencies. J Pediatr. 2001;138(4):570-3.

Seemayer TA, Gross TG, Egeler RM, Pirruccello SJ, Davis JR, Kelly CM, et al. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res. 1995;38(4):471-8.

Lankester AC, Visser LF, Hartwig NG, Bredius RG, Gaspar HB, van der Burg M, et al. Allogeneic stem cell transplantation in X-linked lymphoproliferative disease: two cases in one family and review of the literature. Bone Marrow Transplant. 2005;36(2):99-105.

Fernandes JF, Nichele S, Arcuri LJ, Ribeiro L, Zamperlini-Netto G, Loth G, et al. Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases. Biol Blood Marrow Transplant. 2020;26(10):1923-9.

Klein OR, Buddenbaum J, Tucker N, Chen AR, Gamper CJ, Loeb D, et al. Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. Biol Blood Marrow Transplant. 2017;23(2):325-32.

Uppuluri R, Sivasankaran M, Patel S, Swaminathan VV, Ramanan KM, Ravichandran N, et al. Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Primary Immune Deficiency Disorders in Children: Challenges and Outcome from a Tertiary Care Center in South India. J Clin Immunol. 2019;39(2):182-7.

Smith J, Alfonso JH, Reddivalla N, Angulo P, Katsanis E. Case Report: Haploidentical Bone Marrow Transplantation in Two Brothers With Wiskott-Aldrich Syndrome Using Their Father as the Donor. Front Pediatr. 2021;9:647505.

Sharma A, Rastogi N, Kapoor R, Chatterjee G, Yadav SP. Successful Haploidentical Stem Cell Transplant With Posttransplant Cyclophosphamide in Wiskott-Aldrich Syndrome With Myeloablative Conditioning. J Pediatr Hematol Oncol. 2021;43(2):e230-3.